A Study of Prucalopride For Functional Constipation in Children and Teenagers

NCT ID: NCT04759833

Last Updated: 2024-06-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 175 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-07-13
• Study Completion Date: 2023-11-13

Brief Summary

Functional constipation is a condition when it is very hard to pass a stool that is not due to any other health problem or to medicines being taken. This condition is more common in children and teenagers.

This study has 2 parts:

The main aim of the 1st part of the study is to learn if a medicine called prucalopride can improve bowel movements in children and teenagers with functional constipation. Another aim is to check for side effects from 2 different doses of prucalopride. The main aim of the 2nd part of the study is to continue to check for side effects from 2 different doses of prucalopride.

In the 1st part, at the first visit, the study doctor will check who can take part. Participants who take part will be picked for 1 of 3 treatments by chance.

• A low dose of prucalopride once a day.
• A higher dose of prucalopride once a day.
• A placebo once a day. In this study, a placebo will look like prucalopride but will not have any medicine in it. Participants will be treated with prucalopride or a placebo for 12 weeks.

Participants who took prucalopride will continue to the 2nd part of the study. They will have the same treatment as they did in the 1st part of the study. They will continue with their treatment for another 36 weeks. Participants who took placebo in the 1st part of the study will receive prucalopride in the 2nd part of the study. They will be picked for a low dose or a high dose of prucalopride by chance.

Participants will visit the clinic a few times during treatment. The clinic staff will also telephone the participants, or their parents or caregivers throughout treatment for a check-up 4 weeks after last treatment, the clinic staff will telephone the participants, or their parents or caregivers for a final check-up.

Detailed Description

This study consists of a 12-week double-blind, placebo-controlled part (Part A) followed by a 36-week double-blind safety extension part (Part B). Participants aged 3 to 17 years are planned for randomization in a 1:1:1 ratio to the Low Dose Group, High Dose Group, or matching placebo (placebo-controlled part [Part A]). After completion of Part A, participants in the placebo group will be re-randomized in a 1:1 ratio to the Low Dose Group or the High Dose Group (safety extension part [Part B]). Randomization at study entry will be stratified by toilet-trained status.

Conditions

Constipation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Part A: Placebo

Participants weighing \<50 kilograms (kg) will draw equal volumes from two bottles of placebo oral solution to account for the daily dose assigned or participants weighing ≥ 50 kg will receive two placebo oral tablets, once daily (QD), during 12 weeks in Part A. Prucalopride matching placebo (oral solution or tablet) will be dosed depending on the participant's body weight (BW) at the randomization visit.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Prucalopride-matching placebo oral solution or oral tablets.

Part A: Low Dose Prucalopride

Participants weighing \<50 kg will receive 0.04 milligrams per kilogram (mg/kg) of prucalopride oral solution (will draw the required volume from one bottle of 0.4 milligram per milliliter \[mg/mL\] and one bottle of placebo oral solution), QD or participants weighing ≥50 kg will receive one 2 milligram (mg) of prucalopride oral tablet and one placebo oral tablet, QD, during 12 weeks in Part A. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.

Group Type: EXPERIMENTAL

Prucalopride

Intervention Type: DRUG

Prucalopride oral solution or oral tablets.

Part A: High Dose Prucalopride

Participants weighing \<50 kg will receive 0.08 mg/kg of prucalopride oral solution (will draw the required volume from two bottles of 0.4 mg/mL to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive two 2 mg of prucalopride oral tablets, QD, during 12 weeks of treatment period in Part A. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.

Group Type: EXPERIMENTAL

Prucalopride

Intervention Type: DRUG

Prucalopride oral solution or oral tablets.

Part B: Low Dose Prucalopride

Participants weighing \<50 kg will receive 0.04 mg/kg of prucalopride oral solution (will draw the required volume from one bottle of 0.4 mg/mL and one bottle of placebo oral solution to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive one 2 mg of prucalopride oral tablet and one placebo oral tablet, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.

Group Type: EXPERIMENTAL

Prucalopride

Intervention Type: DRUG

Prucalopride oral solution or oral tablets.

Part B: High Dose Prucalopride

Participants weighing \<50 kg will receive 0.08 mg/kg of prucalopride oral solution (will draw the required volume from two bottles of 0.4 mg/mL to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive two 2 mg of prucalopride oral tablets, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.

Group Type: EXPERIMENTAL

Prucalopride

Intervention Type: DRUG

Prucalopride oral solution or oral tablets.

Interventions

Prucalopride

Prucalopride oral solution or oral tablets.

Intervention Type: DRUG

Placebo

Prucalopride-matching placebo oral solution or oral tablets.

Intervention Type: OTHER

Other Intervention Names

TAK-555; Prucalopride succinate

Eligibility Criteria

Inclusion Criteria

• Participants and/or their parent(s)/caregiver(s)/legally authorized representative(s) have an understanding, ability, and willingness to fully comply with study procedures and restrictions.
• Ability to voluntarily provide written, signed, and dated (personally or via parent[s]/caregiver[s]/legally authorized representative[s]) informed consent/assent as applicable to participate in the study.

Note: Participants and/or parent(s)/caregiver(s)/legally authorized representative(s) (where appropriate depending on age and local regulation) can also provide consent/assent to the sparse Pharmacokinetic (PK) sampling in this study.

• Toilet-trained participants 3 years to 17 years of age, inclusive, or non-toilet-trained participants 6 months to 17 years of age, inclusive.
• Participant weighs greater than or equal to (>=) 5.5 kilograms (kg) (12 pounds [lbs]).
• Male, or non-pregnant, non-lactating female participants who are sexually active and agree to comply with the applicable contraceptive requirements of the protocol or females of non-childbearing potential.

Note: All female participants >= 12 years and/or female participants lesser than (<) 12 years who have started menarche must have a negative serum pregnancy test at screening.

• Participant meets modified Rome IV criteria:

• For child/adolescent (aged > 4 years) functional constipation (H3a):

Participants must have lesser than or equal to (<=) 2 defecations per week and 1 or more of the following occurring at least once per week for a minimum of 1 month:

• >= 1 episode of fecal incontinence per week (only for participants after the acquisition of toileting skills).
• History of retentive posturing or excessive volitional stool retention.
• History of painful or hard bowel movements (BMs).
• Presence of large fecal mass in rectum.
• History of large diameter stools which can obstruct the toilet. In addition, the participant does not satisfy sufficient criteria for a diagnosis of irritable bowel syndrome (IBS) and, after appropriate evaluation, the participants symptoms cannot be fully explained by another medical condition.

For infants/toddler (aged 6 months to <= 4 years) functional constipation (G7):

Participants must have <= 2 defecations per week and >= 1 month of at least 1 of the following:

• History of excessive stool retention
• History of painful or hard BMs
• History of large-diameter stools (in the diaper)
• Presence of a large fecal mass in the rectum

In toilet-trained children, the following additional criteria may be used:

• At least 1 episode/week of incontinence after the acquisition of toileting skills
• History of large-diameter stools which may obstruct the toilet - Participant and/or parent(s)/caregiver(s)/legally authorized representative(s) is willing to discontinue any laxatives during the screening period up to disimpaction and agrees to adhere to the protocol-specified disimpaction and rescue medication rules, if applicable.

To be evaluated prior to randomization:

• Participant has an average of < 3 SBMs (defecations) per week during the screening period and prior to the disimpaction.
• Participant or legally authorized representative (dependent on participant age) is compliant with completing the electronic diary for at least 7 consecutive days preceding the disimpaction.

Exclusion Criteria

• Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product (IP), or clinical or laboratory assessments.
• Any clinically significant abnormal findings on the electrocardiogram (ECG) that indicates a dysrhythmia or conduction abnormalities (such as abnormal heart rate, PR, QRS, or QT).
• Major cardiovascular disease such as: cardiomyopathy, cardiac insufficiency, uncorrected congenital heart disease, symptomatic valve disorders, or septal defects.
• Current or relevant history of physical or psychiatric illness (e.g. severe autism, depression, etc.), any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures.
• Non-retentive fecal incontinence.
• Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum.
• Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the condition being studied (e.g. opioids), or could affect the action, absorption, or disposition of the IP, or clinical or laboratory assessment. (Current use is defined as use within the past 5 days).
• Participants with renal impairment:

• Participants <= 2 years of age with serum creatinine greater than normal (screening sample results using central laboratory pediatric reference ranges).
• Participants > 2 years of age with severe renal impairment or end stage renal disease (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m^2).
• Known or suspected intolerance or hypersensitivity to the IP(s), closely-related compounds, or any of the stated ingredients.
• Known history of alcohol or other substance abuse within the last year.
• Within 30 days prior to the first dose of the IP in the current study:

• Have used any IP.
• Have been enrolled in a clinical study (including vaccine studies) that may or may not include the administration of an IP that, in the investigator's opinion, may impact this study.
• Participant used prucalopride within 10 days prior to the first dose of the IP or has been unsuccessfully treated with prucalopride before.
• Participant meets Rome IV criteria for other Child/Adolescent Functional Gastrointestinal Disorders (FGID) (H1 - H2 and H3b).
• Participant with secondary causes of constipation:

• Endocrine disorders (e.g., hypopituitarism, hypothyroidism, hypercalcemia, pheochromocytoma, glucagon-producing tumors) unless these are controlled by appropriate medical therapy. Participant with uncontrolled diabetes mellitus is to be excluded
• Metabolic disorders (e.g. porphyria, uremia, hypokalemia, hypothyroidism, amyloid neuropathy), unless controlled by appropriate medical therapy
• Neurological disorders (e.g. cerebral tumors, cerebrovascular accidents, multiple sclerosis, meningocele, aganglionosis, hypoganglionosis, hyperganglionosis, autonomic neuropathy, spinal cord injury, Chagas disease
• Organic disorders (known or suspected) of the large bowel (e.g. obstruction from any cause including biliary obstruction, malignancy, intestinal perforation, obstructive ileus, pseudo-obstruction, history of or current anorectal malformations, severe inflammation of the intestinal tract, such as Crohn's disease, ulcerative colitis or toxic megacolon/megarectum, Hirschsprung's disease)
• Celiac disease, cow milk allergy
• Surgery: history of gastrointestinal surgery related or possibly related to the presence of constipation
• Lactose intolerance
• Any of the following clinically significant abnormalities of serum biochemistry:

• Serum aspartate aminotransferase (AST) >1.5 times upper limit of normal (ULN) at screening.
• Serum alanine aminotransferase (ALT) >1.5 times ULN at screening.
• Total bilirubin outside the age-adjusted normal range, except for participants with Gilbert's syndrome.
• Any significant underlying liver disease.
• Participant is not able to swallow the IP (liquid or tablet).
• Participant is pregnant or planning to get pregnant during study period.

To be evaluated prior to randomization:

• Participant has used other disimpaction medication in lieu of the protocol-provided medication.
• Participant has used non-protocol approved medications to induce BMs during the screening period or disimpaction.
• The participant has failed the disimpaction based on the investigator's assessment.
• Worsening of depression and emergence of suicidal thoughts.

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda Development Center Americas, Inc.

INDUSTRY

Sponsor Role: collaborator

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Takeda

Locations

Phoenix Children's Hospital

Phoenix, Arizona, United States

Novak Clinical Research

Tucson, Arizona, United States

Eclipse Clinical Research

Tucson, Arizona, United States

Advanced Research Center, Inc.

Anaheim, California, United States

Children's Hospital of Orange County

Orange, California, United States

University of California, Davis Department of Pediatrics

Sacramento, California, United States

University of California

San Francisco, California, United States

University of Colorado Denver

Aurora, Colorado, United States

Medstar Georgetown University Hospital

Washington D.C., District of Columbia, United States

Direct Helpers Research Center

Hialeah, Florida, United States

Pediatric & Adult Research Center

Kissimmee, Florida, United States

Auzmer Research

Lakeland, Florida, United States

University of Miami - Miller School of Medicine

Miami, Florida, United States

Nicklaus Children's Hospital

Miami, Florida, United States

Florida Research Center, Inc.

Miami, Florida, United States

Orlando Health - APH Center for Digestive Health and Nutrition

Orlando, Florida, United States

The University of Chicago Medical Center

Chicago, Illinois, United States

GI Pediatric Subspecialty Clinic

Peoria, Illinois, United States

Methodist Medical Center of Illinois

Peoria, Illinois, United States

Riley Hospital for Children at Indiana University Health

Indianapolis, Indiana, United States

Willis-Knighton Center for Pediatric Gastroenterology & Advanced Endoscopy

Shreveport, Louisiana, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Baystate Health

Springfield, Massachusetts, United States

Cardinal Glennon Children's Medical Center

St Louis, Missouri, United States

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

CUMC Pediatrics-GI

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

Cyn3rgy Research & Development

Gresham, Oregon, United States

Oregon Health & Science University

Portland, Oregon, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

GI For Kids

Knoxville, Tennessee, United States

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Tekton Research, Inc.

Beaumont, Texas, United States

Cedar Health Research

Dallas, Texas, United States

Allure Health LLC

Friendswood, Texas, United States

Texas Children's Hospital

Houston, Texas, United States

Pediatric Associates

Houston, Texas, United States

Pediatric Center

Richmond, Texas, United States

University of Utah

Salt Lake City, Utah, United States

Pediatric Specialist of Virginia

Fairfax, Virginia, United States

Countries

United States

References

Cuffari C, Spalding W, Achenbach H, Thakur M, Gabriel A. Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation. Contemp Clin Trials Commun. 2023 Apr 30;33:101144. doi: 10.1016/j.conctc.2023.101144. eCollection 2023 Jun.

Reference Type: DERIVED

PMID: 37215389 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://clinicaltrials.takeda.com/study-detail/60363ce520847c001e116bdd

To obtain more information on the study, click here/on this link

Other Identifiers

2022-003221-22

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TAK-555-3010

Identifier Type: -

Identifier Source: org_study_id